NCT02564536View on ClinicalTrials.gov

Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2017

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Chronic Myelomonocytic LeukemiaJuvenile Myelomonocytic LeukemiaAtypical Chronic Myeloid LeukemiaMyeloproliferative NeoplasmMyelodysplastic SyndromesMyelofibrosis
Interventions
DRUG

Pacritinib

-Patients should take pacritinib at approximately the same times every day with a glass of water, with or without food.

DRUG

Decitabine

-From commercial stock

Sponsors

Collaborators (1)

CTI BioPharma
All Listed Sponsors
collaborator

CTI BioPharma

INDUSTRY

lead

Washington University School of Medicine

OTHER